Clinical Trial
Daewoong Pharma Reports Phase 1 Autoimmune Drug Data in US, Shows Over 90% Target Occupancy
Park Hye-mi, PL at Daewoong Pharmaceutical’s Clinical Development Center, presents Phase 1 clinical trial results for the autoimmune disease drug candidate plodicitinib (DWP212525) at ACR Convergence 2026. Provided by Daewoong Pharmaceutical Daewoong Pharmaceutical has confirmed a high level of binding to key target proteins and initial safety results in a Phase 1 clinical trial of ‘plodicitinib’,
2026.11.17